Novo Nordisk A/S $NVO Shares Sold by HM Payson & Co.

HM Payson & Co. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 99.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,518 shares of the company’s stock after selling 346,003 shares during the period. HM Payson & Co.’s holdings in Novo Nordisk A/S were worth $140,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Kingstone Capital Partners Texas LLC lifted its holdings in shares of Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares in the last quarter. Amundi lifted its stake in Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock valued at $331,576,000 after buying an additional 1,627,051 shares in the last quarter. Bank of Montreal Can grew its holdings in Novo Nordisk A/S by 101.4% during the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after buying an additional 1,246,467 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Novo Nordisk A/S by 15,919.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after buying an additional 1,038,137 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its holdings in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after acquiring an additional 935,468 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on NVO. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday, December 23rd. Finally, The Goldman Sachs Group lowered their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Price Performance

NVO opened at $51.19 on Wednesday. The company’s 50 day simple moving average is $49.19 and its 200 day simple moving average is $56.21. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The stock has a market capitalization of $228.55 billion, a PE ratio of 14.88 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non‑injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.
• Positive Sentiment: First‑mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP‑1 market share and trial data show strong weight‑loss results for oral Wegovy, which could help retention vs. competitors. Read More.
• Neutral Sentiment: Macro/ETF flow tailwinds — FDA nod to an oral GLP‑1 is expected to lift healthcare and obesity‑focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.
• Neutral Sentiment: Short‑term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.
• Negative Sentiment: Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.
• Negative Sentiment: Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.
• Negative Sentiment: Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.